Efficacy of acetylcysteine combined with budesonide nebulization in the treatment of neonatal pneumonia and its effect on serum inflammatory factors and oxidative stress indicators
Abstract
To investigate the clinical efficacy of acetylcysteine combined with budesonide nebulization in the treatment of neonatal pneumonia and its effect on serum inflammatory factors and oxidative stress indicators. 97 children with neonatal pneumonia admitted to our hospital from September 2022 to July 2024 were selected and randomly divided into a control group (n=39, receiving budesonide aerosol treatment) and an experimental group (n=38, receiving acetylcysteine combined with budesonide aerosol treatment). The clinical efficacy, inflammatory factor levels [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP)], oxidative stress indicators [superoxide dismutase (SOD), malondialdehyde (MDA) and glutathione peroxidase (GSH-Px)] and the incidence of adverse reactions during treatment were compared between the two groups. After treatment, the total effective rate in the experimental group (97.37%) was higher than that in the control group (82.05%)(P<0.05). The levels of inflammatory factors decreased significantly in both groups. After treatment, the levels of TNF-α, IL-6, and CRP in the experimental group decreased more significantly than those in the control group (P<0.05). The levels of SOD and GSH-Px in the experimental group were significantly higher than those in the control group, and the levels of MDA were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the experimental group (7.89%) was lower than that in the control group (17.95%), but the difference was not statistically significant (P>0.05). Acetylcysteine combined with budesonide has obvious efficacy in the treatment of neonatal pneumonia. It can reduce inflammatory response, improve oxidative stress, and is safe.
References
[1]Ludovichetti F S, Zuccon A, Positello P, et al. Preventive oral hygiene and ventilator-associated pneumonia in paediatric intensive
care unit[J]. Eur J Paediatr Dent, 2022, 23(4): 298-302.
[2]Korang S K, Nava C, Mohana S P, et al. Antibiotics for hospital-acquired pneumonia in neonates and children[J]. Cochrane Database Syst Rev, 2021, 11(11): CD013864.
[3]Heo Y A. Budesonide/Glycopyrronium/Formoterol: A Review in COPD[J]. Drugs, 2021, 81(12): 1411-1422.
[4]Raghu G, Berk M, Campochiaro P A, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress[J]. Curr Neuropharmacol, 2021, 19(8): 1202-1224.
[5]Hooven T A, Polin R A. Pneumonia[J]. Semin Fetal Neonatal Med, 2017, 22(4): 206-213.
[6]Chen J, Zhu Y, Zheng C, et al. Clinical efficacy of budesonide combined with acetylcysteine in the treatment of mycoplasma pneumonia infection[J]. Immun Inflamm Dis, 2023, 11(11): e1068.
[7]Panahi Y, Ghanei M, Rahimi M, et al. Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the
symptoms of patients with COVID-19: An open-label randomized controlled clinical trial[J]. J Med Virol, 2023, 95(1): e28393.
[8]Wang Y, Liu K, Chen C, et al. Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in
children: a clinical observation[J]. Ital J Pediatr, 2023, 49(1): 80.
[9]Chen H, Ma N, Song X, et al. Protective Effects of N-Acetylcysteine on Lipopolysaccharide-Induced Respiratory Inflammation and
Oxidative Stress[J]. Antioxidants (Basel), 2022, 11(5): 879.
[10]Rhee C K, Lim S Y, Lee W Y, et al. The effect of nebulized N-acetylcysteine on the phlegm of chronic obstructive pulmonary disease: the NEWEST study[J]. BMC Pulm Med, 2024, 24(1): 434.
[11]Chen H, Zhou H, Luo C, et al. Efficacy of treatment with N-acetylcysteine inhalation for AECOPD: A propensity-score-matched
cohort study[J]. Clin Respir J, 2023, 17(10): 1038-1047.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
